Boothbay Fund Management LLC Purchases Shares of 41,900 Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Boothbay Fund Management LLC bought a new position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 41,900 shares of the company's stock, valued at approximately $702,000.

Several other institutional investors have also bought and sold shares of CNTA. Price T Rowe Associates Inc. MD lifted its holdings in shares of Centessa Pharmaceuticals by 14.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock valued at $89,854,000 after acquiring an additional 685,371 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in Centessa Pharmaceuticals by 22.0% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company's stock valued at $85,744,000 after purchasing an additional 924,027 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Centessa Pharmaceuticals by 0.3% during the 4th quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company's stock valued at $38,668,000 after purchasing an additional 6,000 shares during the last quarter. Affinity Asset Advisors LLC boosted its position in Centessa Pharmaceuticals by 13.5% in the fourth quarter. Affinity Asset Advisors LLC now owns 1,095,924 shares of the company's stock valued at $18,357,000 after buying an additional 130,312 shares in the last quarter. Finally, Lord Abbett & CO. LLC grew its stake in Centessa Pharmaceuticals by 63.6% during the fourth quarter. Lord Abbett & CO. LLC now owns 440,495 shares of the company's stock worth $7,378,000 after buying an additional 171,290 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company's stock.

Centessa Pharmaceuticals Trading Up 0.8 %

NASDAQ:CNTA traded up $0.11 on Monday, hitting $13.72. 88,908 shares of the stock were exchanged, compared to its average volume of 614,338. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals plc has a 52 week low of $7.75 and a 52 week high of $19.09. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of -8.97 and a beta of 1.53. The company's 50-day moving average price is $14.17 and its 200 day moving average price is $15.78.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.04. On average, equities research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating for the company. Morgan Stanley reissued an "overweight" rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Guggenheim restated a "buy" rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Finally, Piper Sandler assumed coverage on Centessa Pharmaceuticals in a report on Monday, March 31st. They issued an "overweight" rating and a $38.00 price target for the company. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $27.71.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, General Counsel Iqbal J. Hussain sold 2,080 shares of the stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $14.01, for a total value of $29,140.80. Following the transaction, the general counsel now owns 105,386 shares of the company's stock, valued at approximately $1,476,457.86. This represents a 1.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider David M. Chao sold 7,000 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $17.17, for a total value of $120,190.00. Following the transaction, the insider now owns 225,007 shares of the company's stock, valued at $3,863,370.19. The trade was a 3.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 202,353 shares of company stock worth $3,286,478 in the last three months. Insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.